News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Chimeric Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Telix seeks FDA approval for Illucix; Chimeric releases viral vector
Health & Biotech
Here’s how Immutep and other immunotherapy biotechs have changed cancer treatment
Experts
MoneyTalks: Tony Locantro’s 3 contrarian biotech picks in a time of market volatility
Health & Biotech
ASX Health Stocks: Chimeric and Proteomics are making moves to get ready for clinical trials
News
Closing Bell: Small caps win the everywhere war
Health & Biotech
ASX Health Stocks: Chimeric and Recce announce exciting results from Phase 1 clinical trials
Stockhead TV
Market Movers: Oriel Morrison interviews Jennifer Chow, MD and CEO of Chimeric Therapeutics (ASX:CHM)
Health & Biotech
ASX Health Stocks: After TGA approval in Australia, Telix now gets license to sell in Brazil
Health & Biotech
Paul Hopper on whether his new venture Radiopharm Theranostics will be a takeover target, and the keys to biotech success
Health & Biotech
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure
Health & Biotech
Check Up: Rhythm plans TGA submission and pig tissue MOU fails to impress
Health & Biotech
ASX Health Stocks: AnteoTech initiates TGA submission, Zelira jumps 10pc after launching CBD-based acne gel
Escrow Watch
Escrow Watch: Who’s undertaking a release of shares in escrow in September?
Health & Biotech
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space
IPO Watch
IPO Watch: Clarity Pharmaceuticals joins the ASX after completing $92m IPO
Health & Biotech
ScoPo’s Powerplays: Quality names continue to catch a bid as earnings roll in
News